Literature DB >> 18353977

Thrombin induces fibroblast CCL2/JE production and release via coupling of PAR1 to Galphaq and cooperation between ERK1/2 and Rho kinase signaling pathways.

Xiaoling Deng1, Paul F Mercer, Chris J Scotton, Annette Gilchrist, Rachel C Chambers.   

Abstract

Uncontrolled activation of the coagulation cascade after tissue injury has been implicated in both inflammation and tissue fibrosis. Thrombin exerts pluripotent cellular effects via its high-affinity receptor, proteinase-activated receptor-1 (PAR(1)) and signaling via Galpha(i/o), Galpha(q), or Galpha(12/13). Activation of PAR(1) on fibroblasts, a key effector cell in fibrosis, results in the induction of several mediators, including the potent monocyte and fibrocyte chemoattractant CCL2. The aim of this study was to identify the G protein and signaling pathway involved in PAR(1)-mediated CCL2 production and release. Using a novel PAR(1) antagonist that blocks the interaction between PAR(1) and Galpha(q), we report for the first time that PAR(1) coupling to Galpha(q) is essential for thrombin-induced CCL2 gene expression and protein release in murine lung fibroblasts. We further demonstrate that these effects are mediated via the cooperation between ERK1/2 and Rho kinase signaling pathways: a calcium-independent protein kinase C (PKC), c-Raf, and ERK1/2 pathway was found to mediate PAR(1)-induced CCL2 gene transcription, whereas a phospholipase C, calcium-dependent PKC, and Rho kinase pathway influences CCL2 protein release. We propose that targeting the interaction between PAR(1) and Galpha(q) may allow us to selectively interfere with PAR(1) proinflammatory and profibrotic signaling, while preserving the essential role of other PAR(1)-mediated cellular responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353977      PMCID: PMC2397294          DOI: 10.1091/mbc.e07-07-0720

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  52 in total

Review 1.  Role of coagulation cascade proteases in lung repair and fibrosis.

Authors:  R C Chambers
Journal:  Eur Respir J Suppl       Date:  2003-09

2.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation.

Authors:  T K Vu; D T Hung; V I Wheaton; S R Coughlin
Journal:  Cell       Date:  1991-03-22       Impact factor: 41.582

Review 3.  Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice.

Authors:  Christopher D Major; Rosemary J Santulli; Claudia K Derian; Patricia Andrade-Gordon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-04-03       Impact factor: 8.311

4.  Palmitoylation regulates regulators of G-protein signaling (RGS) 16 function. I. Mutation of amino-terminal cysteine residues on RGS16 prevents its targeting to lipid rafts and palmitoylation of an internal cysteine residue.

Authors:  Abel Hiol; Penelope C Davey; James L Osterhout; Abdul A Waheed; Elizabeth R Fischer; Ching-Kang Chen; Graeme Milligan; Kirk M Druey; Teresa L Z Jones
Journal:  J Biol Chem       Date:  2003-03-17       Impact factor: 5.157

5.  Thrombin-elicited contractile responses of aortic smooth muscle.

Authors:  D A Walz; G F Anderson; R E Ciaglowski; M Aiken; J W Fenton
Journal:  Proc Soc Exp Biol Med       Date:  1985-12

6.  PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation.

Authors:  Stefano Fiorucci; Elisabetta Antonelli; Eleonora Distrutti; Beatrice Severino; Roviezzo Fiorentina; Monia Baldoni; Giuseppe Caliendo; Vincenzo Santagada; Antonio Morelli; Giuseppe Cirino
Journal:  Hepatology       Date:  2004-02       Impact factor: 17.425

7.  Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis.

Authors:  Roderick J Phillips; Marie D Burdick; Kurt Hong; Marin A Lutz; Lynne A Murray; Ying Ying Xue; John A Belperio; Michael P Keane; Robert M Strieter
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

8.  Signaling mechanisms involved in protease-activated receptor-1-mediated interleukin-6 production by human gingival fibroblasts.

Authors:  Nobuhisa Tanaka; Takao Morita; Akihiro Nezu; Akihiko Tanimura; Itaru Mizoguchi; Yosuke Tojyo
Journal:  J Pharmacol Exp Ther       Date:  2004-06-21       Impact factor: 4.030

9.  Switch from alphavbeta5 to alphavbeta6 integrin expression protects squamous cell carcinomas from anoikis.

Authors:  Sam M Janes; Fiona M Watt
Journal:  J Cell Biol       Date:  2004-08-02       Impact factor: 10.539

10.  Factor Xa and thrombin, but not factor VIIa, elicit specific cellular responses in dermal fibroblasts.

Authors:  E B Bachli; C M Pech; K M Johnson; D J D Johnson; E G D Tuddenham; J H McVey
Journal:  J Thromb Haemost       Date:  2003-09       Impact factor: 5.824

View more
  25 in total

Review 1.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 2.  Allosteric modulation of protease-activated receptor signaling.

Authors:  I Canto; U J K Soh; J Trejo
Journal:  Mini Rev Med Chem       Date:  2012-08       Impact factor: 3.862

3.  Modulation of PAR(1) signalling by benzimidazole compounds.

Authors:  S Asteriti; S Daniele; F Porchia; M T Dell'Anno; A Fazzini; I Pugliesi; M L Trincavelli; S Taliani; C Martini; M R Mazzoni; A Gilchrist
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

4.  Antagonist minigenes identify genes regulated by parathyroid hormone through G protein-selective and G protein co-regulated mechanisms in osteoblastic cells.

Authors:  J Wang; A Gilchrist; P H Stern
Journal:  Cell Signal       Date:  2010-10-19       Impact factor: 4.315

5.  LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation.

Authors:  Norihiko Sakai; Jerold Chun; Jeremy S Duffield; Takashi Wada; Andrew D Luster; Andrew M Tager
Journal:  FASEB J       Date:  2013-01-15       Impact factor: 5.191

Review 6.  Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease.

Authors:  Tanjina Akter; Richard M Silver; Galina S Bogatkevich
Journal:  Curr Rheumatol Rep       Date:  2014-04       Impact factor: 4.592

7.  Protease-activated receptor 1 inhibition by SCH79797 attenuates left ventricular remodeling and profibrotic activities of cardiac fibroblasts.

Authors:  Dmitry L Sonin; Tetsuro Wakatsuki; Kasi V Routhu; Leanne M Harmann; Matthew Petersen; Jennifer Meyer; Jennifer L Strande
Journal:  J Cardiovasc Pharmacol Ther       Date:  2013-04-17       Impact factor: 2.457

8.  Targeted G-protein inhibition as a novel approach to decrease vagal atrial fibrillation by selective parasympathetic attenuation.

Authors:  Gary L Aistrup; Roger Villuendas; Jason Ng; Annette Gilchrist; Thomas W Lynch; David Gordon; Ivan Cokic; Steven Mottl; Rui Zhou; David A Dean; J Andrew Wasserstrom; Jeffrey J Goldberger; Alan H Kadish; Rishi Arora
Journal:  Cardiovasc Res       Date:  2009-05-20       Impact factor: 10.787

9.  Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury.

Authors:  Chris J Scotton; Malvina A Krupiczojc; Melanie Königshoff; Paul F Mercer; Y C Gary Lee; Naftali Kaminski; John Morser; Joseph M Post; Toby M Maher; Andrew G Nicholson; James D Moffatt; Geoffrey J Laurent; Claudia K Derian; Oliver Eickelberg; Rachel C Chambers
Journal:  J Clin Invest       Date:  2009-08-03       Impact factor: 14.808

10.  Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis.

Authors:  Paul F Mercer; Robin H Johns; Chris J Scotton; Malvina A Krupiczojc; Melanie Königshoff; David C J Howell; Robin J McAnulty; Anuk Das; Andrew J Thorley; Terry D Tetley; Oliver Eickelberg; Rachel C Chambers
Journal:  Am J Respir Crit Care Med       Date:  2008-12-05       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.